Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
Approximately 70% of patients with end-stage renal disease and dialysis have hyperphosphataemia, which is associated with renal osteodystrophy, metastatic calcification and increased mortality and morbidity. Despite dietary restriction and dialysis, most patients will require a phosphate-binding agent to treat this condition. However, phosphate control has not significantly improved over the last two decades, mainly because of the lack of an ideal phosphate-binding agent. Aluminium-based and calcium-based agents are associated with major side-effects despite their efficacy. Although sevelamer hydrochloride represents a step forward in the management of hyperphosphataemia, it has drawbacks and therefore is not the ideal phosphate binder. Lanthanum carbonate is a non-calcium, non-aluminium phosphate-binding agent. It has shown to be effective, well-tolerated and has a positive effect on bone histology.
Albaaj
F
F
Manchester Institute Of Nephrology and Transplantation, Manchester Royal Infirmary, Manchester, UK.
Hutchison
A J
AJ
D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000097:blood; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism; D007811:Lanthanum / Q000378:metabolism / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D010760:Phosphorus Metabolism Disorders / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000009:adverse effects*; D012449:Safety
D010281:Parathyroid Hormone; C119467:lanthanum carbonate; D007811:Lanthanum; D002118:Calcium